Sign Out
Tabulated list of adverse reactions: Adverse reactions are listed as follows by system organ class and frequency category. Frequency categories are defined as very common (ADR ≥1/10), common (1/100 ≤ADR <1/10), uncommon (1/1,000 ≤ADR <1/100), rare (1/10,000 ≤ADR <1/1,000), very rare (ADR <1/10,000) and not known (cannot be estimated from the available data). Within each grouping, adverse reactions are presented in order of decreasing seriousness. (See table.)
Click on icon to see table/diagram/imageDescription of selected adverse reactions: Allergic reactions: Generalised hypersensitivity reactions (e.g. anaphylactic reaction), or immunological reactions such as vasculitis.
Refraction disorders: Changes in blood glucose levels have been known to result in transient visual disturbances, especially at the commencement of treatment. Such disturbances have only been reported in very few cases after initiation of repaglinide treatment. No such cases have led to discontinuation of repaglinide treatment in clinical trials.
Abnormal hepatic function, increased liver enzymes: Isolated cases of increased liver enzymes have been reported during treatment with repaglinide. Most cases were mild and transient, and very few patients discontinued treatment due to increased liver enzymes. In very rare cases, severe hepatic dysfunction has been reported.
Hypersensitivity: Hypersensitivity reactions of the skin may occur as erythema, itching, rashes and urticaria. There is no reason to suspect cross-allergenicity with sulphonylurea due to the difference in chemical structure.
"Inform a doctor or pharmacist immediately of any adverse reactions encountered while using the drug".
View ADR Reporting Link
